Skip to content
2000
Volume 4, Issue 1
  • ISSN: 2666-2906
  • E-ISSN: 2666-2914

Abstract

Hepatitis C continues to present challenges despite the introduction of directly acting antiviral (DAA) treatments. While DAAs have revolutionized the treatment of hepatitis C by offering high cure rates with fewer side effects, there are still several ongoing challenges. Firstly, identifying and diagnosing individuals with hepatitis C remains a significant barrier. Many people with hepatitis C are unaware of their status, leading to delayed diagnosis and treatment initiation. Additionally, certain populations, such as marginalized communities and people who inject drugs, face barriers to accessing testing and treatment services. Secondly, treatment access and affordability are persistent issues. Although DAAs have been hailed for their efficacy, their high costs limit accessibility for many individuals, particularly in low- and middle-income countries. This highlights the need for continued efforts to improve drug affordability and expand access to treatment globally. Thirdly, addressing co-infections and comorbidities is an ongoing challenge in hepatitis C management. Many individuals with hepatitis C also have coexisting conditions, such as HIV or liver cirrhosis, requiring integrated care approaches to effectively manage these complex health needs. Furthermore, despite the effectiveness of DAAs, reinfection remains a concern, especially among high-risk populations. This emphasizes the importance of comprehensive prevention strategies and ongoing monitoring to prevent recurrent infections. Therefore, while the advent of DAAs has transformed the landscape of hepatitis C treatment, continued efforts are necessary to address the challenges of diagnosis, treatment access, co-infections, and reinfection. A comprehensive approach that integrates testing, treatment, and support services is essential to achieve the goal of hepatitis C elimination.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/ijghd/10.2174/0126662906339719241111064412
2024-12-26
2025-09-26

  • From This Site

    /content/journals/ijghd/10.2174/0126662906339719241111064412
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. MartinelloM. SolomonS.S. TerraultN.A. DoreG.J. HepatitisC. Hepatitis C.Lancet2023402104071085109610.1016/S0140‑6736(23)01320‑X37741678
     [Google Scholar]
  2. TsaiW.C. ChiangH.C. ChiuY.C. ChienS.C. ChengP.N. ChiuH.C. Chronic Hepatitis C Virus Infection: An Ongoing Challenge in Screening and Treatment.Life (Basel)20231310196410.3390/life1310196437895346
     [Google Scholar]
  3. WHOGlobal hepatitis report 2024.GenevaWorld Health Organization2024
     [Google Scholar]
  4. WHOGlobal Hepatitis Report 2017.GenevaWorld Health Organization2017
     [Google Scholar]
  5. GuntipalliP. PakalaR. Kumari GaraS. AhmedF. BhatnagarA. Endaya CoronelM.K. RazzackA.A. SolimandoA.G. ThompsonA. AndrewsK. Enebong NyaG. AhmedS. RanaldoR. CozzolongoR. ShahiniE. Worldwide prevalence, genotype distribution and management of hepatitis C.Acta Gastroenterol. Belg.202184463365210.51821/84.4.01534965046
     [Google Scholar]
  6. MartinezM.A. FrancoS. Therapy Implications of Hepatitis C Virus Genetic Diversity.Viruses20201314110.3390/v1301004133383891
     [Google Scholar]
  7. SpearmanC.W. DusheikoG.M. HellardM. SonderupM. HepatitisC. Hepatitis C.Lancet2019394102071451146610.1016/S0140‑6736(19)32320‑731631857
     [Google Scholar]
  8. PetruzzielloA. MariglianoS. LoquercioG. CozzolinoA. CacciapuotiC. Global epidemiology of hepatitis C virus infection: An up-date of the distribution and circulation of hepatitis C virus genotypes.World J. Gastroenterol.201622347824784010.3748/wjg.v22.i34.782427678366
     [Google Scholar]
  9. BlachS. ZeuzemS. MannsM. AltraifI. DubergA-S. MuljonoD.H. WakedI. AlavianS.M. LeeM-H. NegroF. AbaalkhailF. AbdouA. AbdullaM. RachedA.A. AhoI. AkarcaU. Al GhazzawiI. Al KaabiS. Al LawatiF. Al NamaaniK. Al SerkalY. Al-BusafiS.A. Al-DabalL. AlemanS. AlghamdiA.S. AljumahA.A. Al-RomaihiH.E. AnderssonM.I. ArendtV. ArkkilaP. AssiriA.M. BaatarkhuuO. BaneA. Ben-AriZ. BerginC. BessoneF. BihlF. BizriA.R. BlachierM. BlascoA.J. MelloC.E.B. BruggmannP. BruntonC.R. CalinasF. ChanH.L.Y. ChaudhryA. CheinquerH. ChenC-J. ChienR-N. ChoiM.S. ChristensenP.B. ChuangW-L. ChulanovV. CisnerosL. ClausenM.R. CrampM.E. CraxiA. CroesE.A. DalgardO. DaruichJ.R. de LedinghenV. DoreG.J. El-SayedM.H. ErgörG. EsmatG. EstesC. FalconerK. FaragE. FerrazM.L.G. FerreiraP.R. FlisiakR. FrankovaS. GamkrelidzeI. GaneE. García-SamaniegoJ. KhanA.G. GountasI. GoldisA. GottfredssonM. GrebelyJ. GschwantlerM. PessôaM.G. GunterJ. HajarizadehB. HajelssedigO. HamidS. HamoudiW. HatzakisA. HimattS.M. HoferH. HrsticI. HuiY-T. HunyadyB. IdilmanR. JafriW. JahisR. JanjuaN.Z. JarčuškaP. JerumaA. JonassonJ.G. KamelY. KaoJ-H. KaymakogluS. KershenobichD. KhamisJ. KimY.S. KondiliL. KoutoubiZ. KrajdenM. KrarupH. LaiM. LalemanW. LaoW. LavanchyD. LázaroP. LeleuH. LesiO. LesmanaL.A. LiM. LiakinaV. LimY-S. LuksicB. MahomedA. MaimetsM. MakaraM. MaluA.O. MarinhoR.T. MarottaP. MaussS. MemonM.S. CorreaM.C.M. Mendez-SanchezN. MeratS. MetwallyA.M. MohamedR. MorenoC. MouradF.H. MüllhauptB. MurphyK. NdeH. NjouomR. NonkovicD. NorrisS. ObekpaS. OgucheS. OlafssonS. OltmanM. OmedeO. OmuemuC. Opare-SemO. ØvrehusA.L.H. Owusu-OforiS. OyunsurenT.S. PapatheodoridisG. PasiniK. PeltekianK.M. PhillipsR.O. PimenovN. PoustchiH. Prabdial-SingN. QureshiH. RamjiA. Razavi-ShearerD. Razavi-ShearerK. RedaeB. ReesinkH.W. RidruejoE. RobbinsS. RobertsL.R. RobertsS.K. RosenbergW.M. Roudot-ThoravalF. RyderS.D. SafadiR. SagalovaO. SalupereR. SanaiF.M. AvilaJ.F.S. SaraswatV. Sarmento-CastroR. SarrazinC. SchmelzerJ.D. SchréterI. Seguin-DevauxC. ShahS.R. ShararaA.I. SharmaM. ShevaldinA. ShihaG.E. SievertW. SonderupM. SouliotisK. SpeicieneD. SperlJ. StärkelP. StauberR.E. StedmanC. StruckD. SuT-H. SypsaV. TanS-S. TanakaJ. ThompsonA.J. TolmaneI. TomasiewiczK. ValantinasJ. Van DammeP. van der MeerA.J. van ThielI. Van VlierbergheH. VinceA. VogelW. WedemeyerH. WeisN. WongV.W.S. YaghiC. YosryA. YuenM. YunihastutiE. YusufA. ZuckermanE. RazaviH. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: A modelling study.Lancet Gastroenterol. Hepatol.20172316117610.1016/S2468‑1253(16)30181‑928404132
     [Google Scholar]
  10. TahaG. EzraL. Abu-FrehaN. HepatitisC. Elimination: Opportunities and Challenges in 2023.Viruses2023157141310.3390/v1507141337515101
     [Google Scholar]
  11. Roudot-ThoravalF. Epidemiology of hepatitis C virus infection.Clin. Res. Hepatol. Gastroenterol.202145310159610.1016/j.clinre.2020.10159633610022
     [Google Scholar]
  12. LiangT.J. WardJ.W. Hepatitis C in Injection-Drug Users — A Hidden Danger of the Opioid Epidemic.N. Engl. J. Med.2018378131169117110.1056/NEJMp171687129601263
     [Google Scholar]
  13. GoldshearJ.L. SimpsonK.A. KralA.H. WengerL.D. BluthenthalR.N. Novel Routes of Potential Hepatitis C Virus Transmission among People Who Inject Drugs: Secondary Blood Exposures Related to Injection Drug Use.Subst. Use Misuse202156675175710.1080/10826084.2021.187914933769203
     [Google Scholar]
  14. OsmondD.H. CharleboisE. SheppardH.W. PageK. WinkelsteinW. MossA.R. ReingoldA. Comparison of risk factors for hepatitis C and hepatitis B virus infection in homosexual men.J. Infect. Dis.19931671667110.1093/infdis/167.1.668418184
     [Google Scholar]
  15. JordanA.E. PerlmanD.C. NeurerJ. SmithD.J. Des JarlaisD.C. HaganH. Prevalence of hepatitis C virus infection among HIV+ men who have sex with men: A systematic review and meta-analysis.Int. J. STD AIDS201728214515910.1177/095646241663091026826159
     [Google Scholar]
  16. WandelerG. DufourJ.F. BruggmannP. RauchA. HepatitisC. Hepatitis C: A changing epidemic.Swiss Med. Wkly.2015145w1409325658972
     [Google Scholar]
  17. MunariS.C. TraegerM.W. MenonV. LathamN.H. ManoharanL. LuhmannN. BaggaleyR. MacDonaldV. VersterA. SiegfriedN. ConwayB. KleinM. BruneauJ. StoovéM.A. HellardM.E. DoyleJ.S. Determining reinfection rates by hepatitis C testing interval among key populations: A systematic review and meta‐analysis.Liver Int.202343122625264410.1111/liv.1570537817387
     [Google Scholar]
  18. WHOGlobal health sector strategy on viral hepatitis 2016–2021.GenevaWorld Health Organization2016
     [Google Scholar]
  19. WedemeyerH. KheraT. StrunzB. BjörkströmN.K. Reversal of immunity after clearance of chronic HCV infection—all reset?Front. Immunol.20201157116610.3389/fimmu.2020.57116633133084
     [Google Scholar]
  20. BurstowN.J. MohamedZ. Gomaa IA. SonderupM. CookN. WakedI. SpearmanC.W. Taylor-RobinsonS. Hepatitis C treatment: Where are we now?Int. J. Gen. Med.201710395210.2147/IJGM.S12768928255252
     [Google Scholar]
  21. IrshadM. MankotiaD.S. IrshadK. An insight into the diagnosis and pathogenesis of hepatitis C virus infection.World J. Gastroenterol.201319447896790910.3748/wjg.v19.i44.789624307784
     [Google Scholar]
  22. BurgessS.V. HussainiT. YoshidaE.M. Concordance of sustained virologic response at weeks 4, 12 and 24 post-treatment of hepatitis c in the era of new oral direct-acting antivirals: A concise review.Ann. Hepatol.201615215415926845592
     [Google Scholar]
  23. National Institutes of Health Consensus Development Conference Panel statement: Management of hepatitis C.Hepatology1997263Suppl. 12S10S9305656
     [Google Scholar]
  24. CarithersR.L.Jr EmersonS.S. Therapy of hepatitis C: Meta-analysis of interferon alfa-2b trials.Hepatology199726S3Suppl. 183S88S10.1002/hep.5102607159305670
     [Google Scholar]
  25. DavisG.L. Esteban-MurR. RustgiV. HoefsJ. GordonS.C. TrepoC. ShiffmanM.L. ZeuzemS. CraxiA. LingM.H. AlbrechtJ. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C.N. Engl. J. Med.1998339211493149910.1056/NEJM1998111933921029819447
     [Google Scholar]
  26. LiuB. McGilvrayI. ChenL. IFN- λ : A new class of interferon with distinct functions-implications for hepatitis C virus research.Gastroenterol. Res. Pract.201520151910.1155/2015/79646126078754
     [Google Scholar]
  27. FriedM.W. ShiffmanM.L. ReddyK.R. SmithC. MarinosG. GonçalesF.L.Jr HäussingerD. DiagoM. CarosiG. DhumeauxD. CraxiA. LinA. HoffmanJ. YuJ. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.N. Engl. J. Med.20023471397598210.1056/NEJMoa02004712324553
     [Google Scholar]
  28. MannsM.P. McHutchisonJ.G. GordonS.C. RustgiV.K. ShiffmanM. ReindollarR. GoodmanZ.D. KouryK. LingM.H. AlbrechtJ.K. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial.Lancet2001358928695896510.1016/S0140‑6736(01)06102‑511583749
     [Google Scholar]
  29. SulkowskiM.S. CooperC. HunyadyB. JiaJ. OgurtsovP. Peck-RadosavljevicM. ShiffmanM.L. YurdaydinC. DalgardO. Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C.Nat. Rev. Gastroenterol. Hepatol.20118421222310.1038/nrgastro.2011.2121386812
     [Google Scholar]
  30. PawlotskyJ.M. FeldJ.J. ZeuzemS. HoofnagleJ.H. From non-A, non-B hepatitis to hepatitis C virus cure.J. Hepatol.2015621Suppl.S87S9910.1016/j.jhep.2015.02.00625920094
     [Google Scholar]
  31. ChahineE.B. KelleyD. Childs-KeanL.M. Sofosbuvir/Velpatasvir/Voxilaprevir: A Pan-Genotypic Direct-Acting Antiviral Combination for Hepatitis C.Ann. Pharmacother.201852435236310.1177/106002801774150829115151
     [Google Scholar]
  32. ColpittsC.C. El-SaghireH. PochetN. SchusterC. BaumertT.F. High-throughput approaches to unravel hepatitis C virus-host interactions.Virus Res.2016218182410.1016/j.virusres.2015.09.01326410623
     [Google Scholar]
  33. MatthewA.N. ZephyrJ. Nageswara RaoD. HenesM. KamranW. KosovrastiK. HedgerA.K. LockbaumG.J. TimmJ. AliA. Kurt YilmazN. SchifferC.A. Avoiding Drug Resistance by Substrate Envelope-Guided Design: Toward Potent and Robust HCV NS3/4A Protease Inhibitors.MBio2020112e00172-2010.1128/mBio.00172‑2032234812
     [Google Scholar]
  34. GötteM. FeldJ.J. Direct-acting antiviral agents for hepatitis C: Structural and mechanistic insights.Nat. Rev. Gastroenterol. Hepatol.201613633835110.1038/nrgastro.2016.6027147491
     [Google Scholar]
  35. GeorgopapadakouN. Discontinued drugs in 2005: Anti-infectives.Expert Opin. Investig. Drugs200716111010.1517/13543784.16.1.117155849
     [Google Scholar]
  36. ParsyC.C. AlexandreF.R. BidauV. BonnaterreF. BrandtG. CailletC. CappelleS. ChavesD. ConvardT. DerockM. GlouxD. GriffonY. LallosL.B. LeroyF. LiuzziM. LoiA.G. MoulatL. ChiaraM. RahaliH. RoquesV. RosinovskyE. SavinS. SeiferM. StandringD. SurlerauxD. Discovery and structural diversity of the hepatitis C virus NS3/4A serine protease inhibitor series leading to clinical candidate IDX320.Bioorg. Med. Chem. Lett.201525225427543610.1016/j.bmcl.2015.09.00926410074
     [Google Scholar]
  37. HeY. StaschkeK.A. TanS.L. HCV NS5A: A multifunctional regulator of cellular pathways and virus replication.Hepatitis C Viruses: Genomes and Molecular BiologyRockville Pike, BethesdaNational Library Of Medicine2006
     [Google Scholar]
  38. ZhouZ. ZhangJ. ZhouE. RenC. WangJ. WangY. Small molecule NS5B RdRp non-nucleoside inhibitors for the treatment of HCV infection: A medicinal chemistry perspective.Eur. J. Med. Chem.202224011459510.1016/j.ejmech.2022.11459535868125
     [Google Scholar]
  39. GhanyM.G. NelsonD.R. StraderD.B. ThomasD.L. SeeffL.B. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases.Hepatology20115441433144410.1002/hep.2464121898493
     [Google Scholar]
  40. RocheB. CoillyA. Roque-AfonsoA.M. SamuelD. Interferon-Free Hepatitis C Treatment before and after Liver Transplantation: The Role of HCV Drug Resistance.Viruses2015795155516810.3390/v709286426404355
     [Google Scholar]
  41. CortezK.J. KottililS. Beyond interferon: Rationale and prospects for newer treatment paradigms for chronic hepatitis C.Ther. Adv. Chronic Dis.20156141410.1177/204062231455193425553238
     [Google Scholar]
  42. BaconB.R. GordonS.C. LawitzE. MarcellinP. VierlingJ.M. ZeuzemS. PoordadF. GoodmanZ.D. SingsH.L. BoparaiN. BurroughsM. BrassC.A. AlbrechtJ.K. EstebanR. Boceprevir for previously treated chronic HCV genotype 1 infection.N. Engl. J. Med.2011364131207121710.1056/NEJMoa100948221449784
     [Google Scholar]
  43. JacobsonI.M. McHutchisonJ.G. DusheikoG. Di BisceglieA.M. ReddyK.R. BzowejN.H. MarcellinP. MuirA.J. FerenciP. FlisiakR. GeorgeJ. RizzettoM. ShouvalD. SolaR. TergR.A. YoshidaE.M. AddaN. BengtssonL. SankohA.J. KiefferT.L. GeorgeS. KauffmanR.S. ZeuzemS. Telaprevir for previously untreated chronic hepatitis C virus infection.N. Engl. J. Med.2011364252405241610.1056/NEJMoa101291221696307
     [Google Scholar]
  44. FerenciP. CaruntuF.A. LengyelG. MessingerD. BakalosG. FlisiakR. Boceprevir Plus Peginterferon Alfa-2a/Ribavirin in Treatment-Naïve Hepatitis C Virus Genotype 1 Patients: International Phase IIIb/IV TriCo Trial.Infect. Dis. Ther.20165211312410.1007/s40121‑016‑0110‑527228998
     [Google Scholar]
  45. SamainA. Duval-ModesteA.B. JolyP. LeblancC. MassyN. CourvilleP. GoriaO. RiachiG. First case of drug rash eosinophilia and systemic symptoms due to boceprevir.J. Hepatol.201460489189310.1016/j.jhep.2013.12.00824333861
     [Google Scholar]
  46. HynickaL.M. HeilE.L. Anemia management in patients with chronic viral hepatitis C.Ann. Pharmacother.201347222823610.1345/aph.1R51323386076
     [Google Scholar]
  47. VourvahisM. PlotkaA. KantaridisC. FangA. HeeraJ. The effects of boceprevir and telaprevir on the pharmacokinetics of maraviroc: An open-label, fixed-sequence study in healthy volunteers.J. Acquir. Immune Defic. Syndr.201465556457010.1097/QAI.000000000000009024346637
     [Google Scholar]
  48. GentileI. BuonomoA.R. BorgiaF. ZappuloE. CastaldoG. BorgiaG. MK-5172: A second-generation protease inhibitor for the treatment of hepatitis C virus infection.Expert Opin. Investig. Drugs201423571972810.1517/13543784.2014.90204924666106
     [Google Scholar]
  49. PillaiyarT. NamasivayamV. ManickamM. Macrocyclic HepatitisC. Macrocyclic Hepatitis C Virus NS3/4A Protease Inhibitors: An Overview of Medicinal Chemistry.Curr. Med. Chem.201623293404344710.2174/092986732366616051012252527160539
     [Google Scholar]
  50. LinT.I. LenzO. FanningG. VerbinnenT. DelouvroyF. ScholliersA. VermeirenK. RosenquistÅ. EdlundM. SamuelssonB. VrangL. de KockH. WigerinckP. RaboissonP. SimmenK. In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor.Antimicrob. Agents Chemother.20095341377138510.1128/AAC.01058‑0819171797
     [Google Scholar]
  51. TanwarS. TremblingP.M. DusheikoG.M. TMC435 for the treatment of chronic hepatitis C.Expert Opin. Investig. Drugs20122181193120910.1517/13543784.2012.69039222616626
     [Google Scholar]
  52. PascaleA. SerfatyL. Triple therapy with first generation HCV protease inhibitors: Lead-in or no lead-in phase?J. Hepatol.201358239139410.1016/j.jhep.2012.09.02323063419
     [Google Scholar]
  53. MaasoumyB. PortK. MarkovaA.A. SerranoB.C. Rogalska-TarantaM. SollikL. MixC. KirschnerJ. MannsM.P. WedemeyerH. CornbergM. Eligibility and safety of triple therapy for hepatitis C: Lessons learned from the first experience in a real world setting.PLoS One201382e5528510.1371/journal.pone.005528523383319
     [Google Scholar]
  54. MannsM.P. MaasoumyB. Breakthroughs in hepatitis C research: From discovery to cure.Nat. Rev. Gastroenterol. Hepatol.202219853355010.1038/s41575‑022‑00608‑835595834
     [Google Scholar]
  55. DeterdingK. Höner zu SiederdissenC. PortK. SolbachP. SollikL. KirschnerJ. MixC. CornbergJ. WorzalaD. MixH. MannsM.P. CornbergM. WedemeyerH. Improvement of liver function parameters in advanced HCV ‐associated liver cirrhosis by IFN ‐free antiviral therapies.Aliment. Pharmacol. Ther.201542788990110.1111/apt.1334326250762
     [Google Scholar]
  56. GittoS. GamalN. AndreoneP. NS 5A inhibitors for the treatment of hepatitis C infection.J. Viral Hepat.201724318018610.1111/jvh.1265727925362
     [Google Scholar]
  57. LokA.S. GardinerD.F. LawitzE. MartorellC. EversonG.T. GhalibR. ReindollarR. RustgiV. McPheeF. Wind-RotoloM. PerssonA. ZhuK. DimitrovaD.I. EleyT. GuoT. GraselaD.M. PasquinelliC. Preliminary study of two antiviral agents for hepatitis C genotype 1.N. Engl. J. Med.2012366321622410.1056/NEJMoa110443022256805
     [Google Scholar]
  58. PapalucaT. RobertsS.K. StrasserS.I. StuartK.A. FarrellG. MacQuillanG. DoreG.J. WadeA.J. GeorgeJ. HazeldineS. O’BeirneJ. WiggA. FisherL. McGarityB. SawhneyR. SinclairM. ThomasJ. ValiozisI. WeltmanM. WilsonM. WoodwardA. AhlenstielG. HaqueM. LevyM. PrewettE. SievertW. SoodS. TseE. ValaydonZ. BowdenS. DouglasM. NewK. O’KeefeJ. HellardM. DoyleJ. StooveM. ThompsonA.J. Efficacy and Safety of Sofosbuvir/Velpatasvir/Voxilaprevir for Hepatitis C Virus (HCV) NS5A-Inhibitor Experienced Patients With Difficult to Cure Characteristics.Clin. Infect. Dis.2021739e3288e329510.1093/cid/ciaa131832887983
     [Google Scholar]
  59. ShahabM. KhanA. KhanS.A. ZhengG. Unraveling the mechanisms of Sofosbuvir resistance in HCV NS3/4A protease: Structural and molecular simulation-based insights.Int. J. Biol. Macromol.2024267Pt 213162910.1016/j.ijbiomac.2024.13162938631585
     [Google Scholar]
  60. AbrahamG.M. SpoonerL.M. Sofosbuvir in the treatment of chronic hepatitis C: New dog, new tricks.Clin. Infect. Dis.201459341141510.1093/cid/ciu26524748524
     [Google Scholar]
  61. JangE.S. KimK.A. KimY.S. KimI.H. LeeB.S. LeeY.J. ChungW.J. JeongS.H. Real‐life effectiveness and safety of the daclatasvir/asunaprevir combination therapy for genotype 1b chronic hepatitis C patients: An emphasis on the pretreatment NS5A resistance‐associated substitution test.J. Med. Virol.201991122158216510.1002/jmv.2557531452206
     [Google Scholar]
  62. SabryN. KamelA.M. CordieA. EsmatG. Daclatasvir as a hepatitis C infection treatment option: An up-to-date evaluation.Expert Opin. Pharmacother.202324215917010.1080/14656566.2022.214588336369914
     [Google Scholar]
  63. El-SayedM. ElserafyM. El RazikyM. ElakelW. SaadY. FayadT. KoranyM. MehrezM. SalamaR. MahrousM. ZakiA. HassanyM. AmmarI. ElsaeedK. ElshazlyY. DossW. Efficacy and safety of ombitasvir/paritaprevir/ritonavir-based therapy in HCV patients with chronic kidney disease.Arab J. Gastroenterol.2023241293310.1016/j.ajg.2022.10.00136813580
     [Google Scholar]
  64. LiouB.H. SunH.Y. YangC.J. SyueL.S. LeeY.L. TangH.J. TsaiH.C. LinC.Y. ChenT.C. LeeC.Y. HuangS.H. LiuC.W. LuP.L. LinS.P. WangN.C. ChengA. KoW.C. ChengS.H. HungC.C. Real-World Experience with Coformulated Ledipasvir and Sofosbuvir for HIV-Positive Patients with HCV Genotype 2 Infection: A Multicenter, Retrospective Study.Infect. Dis. Ther.202110282783810.1007/s40121‑021‑00424‑833733316
     [Google Scholar]
  65. DeutschL. HouriI. Ben-AriZ. ShlomaiA. VeitsmanE. Cohen-EzraO. IssacharA. MorO. GozlanY. BruckR. MenachemY. Zelber-SagiS. KatchmanH. ShiboletO. Ombitasvir/paritaprevir/ritonavir & dasabuvir ± ribavirin following protease inhibitors failure - a prospective multi-centre trial.BMC Infect. Dis.202020126410.1186/s12879‑020‑4921‑332245397
     [Google Scholar]
  66. ToyodaH. Sofosbuvir/velpatasvir and glecaprevir/pibrentasvir: How should we choose among these two latest and probably the last regimens?Hepatol. Res.2022521081581610.1111/hepr.1382836181692
     [Google Scholar]
  67. FeldJ.J. JacobsonI.M. HézodeC. AsselahT. RuaneP.J. GruenerN. AbergelA. MangiaA. LaiC.L. ChanH.L.Y. MazzottaF. MorenoC. YoshidaE. ShafranS.D. TownerW.J. TranT.T. McNallyJ. OsinusiA. SvarovskaiaE. ZhuY. BrainardD.M. McHutchisonJ.G. AgarwalK. ZeuzemS. Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection.N. Engl. J. Med.2015373272599260710.1056/NEJMoa151261026571066
     [Google Scholar]
  68. VolpicelliL. BiliottiE. MilitoC. CruciataA. SpazianteM. Rivano CapparucciaM. TalianiG. MezzaromaI. Glecaprevir/pibrentasvir ultra-short treatment to cure HCV infection: Case report and literature review.Infez. Med.202028461662033257639
     [Google Scholar]
  69. Gonzalez-SernaA. MaciasJ. Corma-GomezA. TellezF. CucurullJ. RealL.M. GranadosR. Rivero-JuarezA. Hernandez-QueroJ. MerinoD. PalaciosR. RiosM.J. ColladoA. PinedaJ.A. High efficacy of glecaprevir/pibrentasvir for HCV-infected individuals with active drug use.J. Infect.202285332232610.1016/j.jinf.2022.06.00535700867
     [Google Scholar]
  70. LiuC.H. KaoJ.H. Acute hepatitis C virus infection: Clinical update and remaining challenges.Clin. Mol. Hepatol.202329362364210.3350/cmh.2022.034936800699
     [Google Scholar]
  71. AduP.A. RossiC. BinkaM. WongS. WiltonJ. WongJ. ButtZ.A. BartlettS. JeongD. PearceM. DarvishianM. YuA. AlvarezM. Velásquez GarcíaH.A. KrajdenM. JanjuaN.Z. HCV reinfection rates after cure or spontaneous clearance among HIV‐infected and uninfected men who have sex with men.Liver Int.202141348249310.1111/liv.1476233305525
     [Google Scholar]
  72. ShoukryN.H. Towards a Systems Immunology Approach to Understanding Correlates of Protective Immunity against HCV.Viruses2021139187110.3390/v1309187134578451
     [Google Scholar]
  73. Falade-NwuliaO. SulkowskiM.S. MerkowA. LatkinC. MehtaS.H. Understanding and addressing hepatitis C reinfection in the oral direct‐acting antiviral era.J. Viral Hepat.201825322022710.1111/jvh.1285929316030
     [Google Scholar]
  74. GobranS.T. AncutaP. ShoukryN.H. A tale of two viruses: Immunological insights into HCV/HIV coinfection.Front. Immunol.20211272641910.3389/fimmu.2021.72641934456931
     [Google Scholar]
  75. Hosseini-HooshyarS. HajarizadehB. BajisS. LawM. JanjuaN.Z. FiererD.S. ChromyD. RockstrohJ.K. MartinT.C.S. IngilizP. HungC.C. DoreG.J. MartinelloM. MatthewsG.V. Risk of hepatitis C reinfection following successful therapy among people living with HIV: A global systematic review, meta-analysis, and meta-regression.Lancet HIV202296e414e42710.1016/S2352‑3018(22)00077‑735659336
     [Google Scholar]
  76. ElliottT. CookeG.S. GarveyL. Interventions to reduce acute hepatitis C virus in HIV-positive MSM.Curr. Opin. Infect. Dis.20203311910.1097/QCO.000000000000061431789696
     [Google Scholar]
/content/journals/ijghd/10.2174/0126662906339719241111064412
Loading
Hepatitis C: Evolving Epidemiology, Treatment Landscape, and Current Challenges
Int J Gastroenterol Hepatol Dis 4, E26662906339719 (2025); https://doi.org/10.2174/0126662906339719241111064412
/content/journals/ijghd/10.2174/0126662906339719241111064412
/content/journals/ijghd/10.2174/0126662906339719241111064412
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): directly acting antiviral; genotype; Hepatitis C; hepatocellular carcinoma; liver cirrhosis; marginalized communities

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test